[go: up one dir, main page]

PE20140392A1 - HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA - Google Patents

HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA

Info

Publication number
PE20140392A1
PE20140392A1 PE2013000904A PE2013000904A PE20140392A1 PE 20140392 A1 PE20140392 A1 PE 20140392A1 PE 2013000904 A PE2013000904 A PE 2013000904A PE 2013000904 A PE2013000904 A PE 2013000904A PE 20140392 A1 PE20140392 A1 PE 20140392A1
Authority
PE
Peru
Prior art keywords
oxobutil
ona
pyrimidin
bis
amino
Prior art date
Application number
PE2013000904A
Other languages
English (en)
Inventor
Ki Sook Park
Jung Min Yun
Bong Chan Kim
Kyu Young Kim
Ji Hye Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140392(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of PE20140392A1 publication Critical patent/PE20140392A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN HIDRATO DE SAL DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOMETIL)-5,8-DIHIDRO-PIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUOROPIPERIDIN-2-ONA QUE COMPRENDE UN CONTENIDO DE AGUA EN UN RANGO DE 3,5% Y 5,5% Y POSEE VALORES DEL PICO (2 THETA) EN EL DIFRACTOGRAMA DE XRD SON DE 15�, 18�, 20�, 21� Y 23�. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHO HIDRATO ES UTIL EN EL TRATAMIENTO O PREVENCION DE LA DIABETES U OBESIDAD
PE2013000904A 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA PE20140392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100107868 2010-11-01

Publications (1)

Publication Number Publication Date
PE20140392A1 true PE20140392A1 (es) 2014-03-22

Family

ID=45995015

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2018000088A PE20180464A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2013000904A PE20140392A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
PE2023001454A PE20240220A1 (es) 2010-11-01 2011-10-31 SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2018000088A PE20180464A1 (es) 2010-11-01 2011-10-31 HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2023001454A PE20240220A1 (es) 2010-11-01 2011-10-31 SAL TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA 1,5 HIDRATO

Country Status (29)

Country Link
US (1) US8859567B2 (es)
EP (1) EP2635580B1 (es)
JP (1) JP6193762B2 (es)
KR (1) KR101446789B1 (es)
CN (1) CN103189375B (es)
AP (1) AP3287A (es)
AR (1) AR083591A1 (es)
AU (1) AU2011324253B2 (es)
BR (1) BR112013010586A2 (es)
CA (1) CA2814357C (es)
CL (1) CL2013001137A1 (es)
CO (1) CO6710945A2 (es)
DO (1) DOP2013000090A (es)
EA (1) EA024679B1 (es)
EC (1) ECSP13012599A (es)
GE (1) GEP20156218B (es)
IL (1) IL225808A (es)
MA (1) MA34625B1 (es)
MX (1) MX341584B (es)
MY (1) MY156428A (es)
NZ (1) NZ609644A (es)
PE (3) PE20180464A1 (es)
PH (1) PH12013500685A1 (es)
SG (1) SG189931A1 (es)
TW (1) TWI519533B (es)
UA (1) UA106445C2 (es)
UY (1) UY33696A (es)
WO (1) WO2012060590A2 (es)
ZA (1) ZA201302646B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2007752T1 (sl) 2006-03-31 2010-12-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
SG11201507117XA (en) 2013-03-06 2015-10-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
PH12023550900A1 (en) * 2020-10-13 2024-03-04 Lg Chemical Ltd Oral combined formulation including gemigliptin and dapagliflozin and preparation method therefor
KR20250137744A (ko) 2024-03-11 2025-09-19 엠에프씨 주식회사 제미글립틴의 신규 결정형 및 이의 제조방법
KR20250147756A (ko) 2024-03-27 2025-10-14 엠에프씨 주식회사 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법
KR20250155700A (ko) 2024-04-24 2025-10-31 주식회사 다산제약 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물
CN119285630B (zh) * 2024-09-05 2025-05-27 安徽峆一药业股份有限公司 一种吉格列汀草酸盐及其晶型、制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1554256B1 (en) * 2002-07-15 2009-12-09 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2006516573A (ja) * 2003-01-31 2006-07-06 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
PE20180464A1 (es) 2018-03-06
AR083591A1 (es) 2013-03-06
ZA201302646B (en) 2014-01-29
JP2013540810A (ja) 2013-11-07
TW201245189A (en) 2012-11-16
NZ609644A (en) 2016-02-26
PH12013500685A1 (en) 2015-10-02
AU2011324253A1 (en) 2013-05-02
MX341584B (es) 2016-08-25
GEP20156218B (en) 2015-01-12
EP2635580B1 (en) 2015-08-12
UY33696A (es) 2012-04-30
KR20120046069A (ko) 2012-05-09
EA201390644A1 (ru) 2014-11-28
CA2814357A1 (en) 2012-05-10
WO2012060590A3 (en) 2012-06-28
AU2011324253B2 (en) 2015-10-29
TWI519533B (zh) 2016-02-01
US20130203787A1 (en) 2013-08-08
CN103189375B (zh) 2016-08-10
IL225808A (en) 2016-08-31
KR101446789B1 (ko) 2014-10-01
JP6193762B2 (ja) 2017-09-06
AP3287A (en) 2015-05-31
MY156428A (en) 2016-02-26
IL225808A0 (en) 2013-06-27
MX2013004776A (es) 2013-11-04
CN103189375A (zh) 2013-07-03
EP2635580A2 (en) 2013-09-11
SG189931A1 (en) 2013-06-28
US8859567B2 (en) 2014-10-14
CO6710945A2 (es) 2013-07-15
ECSP13012599A (es) 2013-07-31
PE20240220A1 (es) 2024-02-16
MA34625B1 (fr) 2013-10-02
CL2013001137A1 (es) 2013-09-06
DOP2013000090A (es) 2018-06-30
EP2635580A4 (en) 2014-04-02
EA024679B1 (ru) 2016-10-31
BR112013010586A2 (pt) 2016-08-09
AP2013006866A0 (en) 2013-05-31
WO2012060590A2 (en) 2012-05-10
UA106445C2 (ru) 2014-08-26
CA2814357C (en) 2015-07-07

Similar Documents

Publication Publication Date Title
PE20140392A1 (es) HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETIL)-5,8-DI-HIDROPIRIDO[3,4-d]PIRIMIDIN-7(6H)-IL]-4-OXOBUTIL}-5,5-DIFLUORO-PIPERIDIN-2-ONA
BR112013026690A2 (pt) composição compreendendo bactérias probióticas capazes de restaurar o efeito de barreira do estomago que é perdido durante o tratamento farmacológico da hiperacidez gástrica
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
UY30364A1 (es) Arilimidazolonas y ariltriazolonas sustituidas asi como su uso
CR10976A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
BR112014005440A2 (pt) composição compreendendo n-acetilcisteína e/ou lisozima gastroprotegida microencapsulada em associação com bactérias probióticas capazes de restaurar o efeito de barreira do próprio estômago que é perdido durante o tratamento farmacológico de hiperacidez gástrica
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
UY31765A (es) Dihidropirazolonas sustituidas y su uso
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BR112013023337A2 (pt) hidrocloreto de ambroxol para tratamento de faringite aguda, uso do mesmo, composição aquosa borrifável e dispositivo borrifador para aplicação local
UA41637U (ru) Состав для физиотерапевтического лечения абдоминального ожирения больных с метаболическим синдромом и остеоартрозом опорных суставов
CR10449A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CR20110317A (es) Derivados bicíclicos de morfina-6-glucuronido, su preparación y su aplicación en terapéutica
CO7160048A2 (es) Composición para higiéne íntima extendida, proceso de producción y uso
TN2014000526A1 (en) Injectable supersaturated acetaminophen solution for spinal administration
MX2012006194A (es) Composiciones analgesicas que comprenden quercetina mas ketorolaco.
CL2011002626A1 (es) Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos.

Legal Events

Date Code Title Description
FC Refusal